Adding Liraglutide to High Dose Insulin: Breaking the Cycle

NCT01505673 on ClinicalTrials.gov · last registry update 2018-01-16

Finished June 2016, after enrolling 71 people. Primary outcome, as filed: Glycemic Control Measured by HbA1c. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Ildiko Lingvay
Sponsor type: Other
Enrollment: 71
Started: 2012-01
Primary completion: 2016-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycemic Control Measured by HbA1c

Conditions studied

Type 2 Diabetes Mellitus · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.